CN109843884B - 作为pde1抑制剂的咪唑并吡嗪酮、吡唑并嘧啶酮和吡唑并吡啶酮 - Google Patents

作为pde1抑制剂的咪唑并吡嗪酮、吡唑并嘧啶酮和吡唑并吡啶酮 Download PDF

Info

Publication number
CN109843884B
CN109843884B CN201780060932.7A CN201780060932A CN109843884B CN 109843884 B CN109843884 B CN 109843884B CN 201780060932 A CN201780060932 A CN 201780060932A CN 109843884 B CN109843884 B CN 109843884B
Authority
CN
China
Prior art keywords
methyl
phenyl
pyrazin
imidazo
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201780060932.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN109843884A (zh
Inventor
J·凯勒
L·K·拉斯穆森
M·朗格路
M·杰辛
P·J·V·维塔尔
K·朱尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
H Lundbeck AS
Original Assignee
H Lundbeck AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck AS filed Critical H Lundbeck AS
Publication of CN109843884A publication Critical patent/CN109843884A/zh
Application granted granted Critical
Publication of CN109843884B publication Critical patent/CN109843884B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201780060932.7A 2016-10-18 2017-10-17 作为pde1抑制剂的咪唑并吡嗪酮、吡唑并嘧啶酮和吡唑并吡啶酮 Expired - Fee Related CN109843884B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA201600643 2016-10-18
DKPA201600643 2016-10-18
DKPA201700191 2017-03-14
DKPA201700191 2017-03-14
PCT/EP2017/076481 WO2018073251A1 (en) 2016-10-18 2017-10-17 Imidazopyrazinones, pyrazolopyrimidinones and pyrazolopyridinones as pde1 inhibitors

Publications (2)

Publication Number Publication Date
CN109843884A CN109843884A (zh) 2019-06-04
CN109843884B true CN109843884B (zh) 2022-03-04

Family

ID=60186253

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780060932.7A Expired - Fee Related CN109843884B (zh) 2016-10-18 2017-10-17 作为pde1抑制剂的咪唑并吡嗪酮、吡唑并嘧啶酮和吡唑并吡啶酮

Country Status (6)

Country Link
US (1) US10633382B2 (enExample)
EP (1) EP3529250B1 (enExample)
JP (1) JP7112413B2 (enExample)
CN (1) CN109843884B (enExample)
ES (1) ES2967489T3 (enExample)
WO (1) WO2018073251A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201629064A (zh) 2014-10-10 2016-08-16 Ｈ 朗德貝克公司 作爲ｐｄｅ１抑制劑之三唑並吡酮
JO3627B1 (ar) 2015-04-30 2020-08-27 H Lundbeck As إيميدازو بيرازينونات على هيئة مثبطات pde1
TWI729109B (zh) 2016-04-12 2021-06-01 丹麥商Ｈ 朗德貝克公司 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮
EP3529250B1 (en) 2016-10-18 2023-12-06 H. Lundbeck A/S Imidazopyrazinones, pyrazolopyrimidinones and pyrazolopyridinones as pde1 inhibitors
HUE050403T2 (hu) 2016-10-28 2020-12-28 H Lundbeck As Imidazopirazinonokkal végzett kombinációs kezelések pszichiátriai és/vagy kognitív betegségek kezelésére
WO2018078042A1 (en) 2016-10-28 2018-05-03 H. Lundbeck A/S Combination treatments comprising administration of imidazopyrazinones
US20210205310A1 (en) 2018-05-25 2021-07-08 Intra-Cellular Therapies, Inc. Organic compounds
CN116874495B (zh) * 2023-06-30 2025-10-10 中山大学 一种吡啶并二氢呋喃酮类衍生物及其制备方法和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101983199A (zh) * 2008-04-02 2011-03-02 贝林格尔.英格海姆国际有限公司 1-杂环基-1，5-二氢-吡唑并[3，4-d]嘧啶-4-酮衍生物及其作为pde9a调节剂的用途
CN102143965A (zh) * 2008-09-08 2011-08-03 贝林格尔.英格海姆国际有限公司 吡唑并嘧啶酮及其在治疗中枢神经系统疾病中的用途
CN102292340A (zh) * 2009-01-26 2011-12-21 辉瑞大药厂 用作pde9 抑制剂的氨基-杂环类化合物

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB973361A (en) 1960-05-11 1964-10-28 Ciba Ltd Pyrazolo-pyrimidines and process for their manufacture
DE19709877A1 (de) * 1997-03-11 1998-09-17 Bayer Ag 1,5-Dihydro-pyrazolo[3,4-d]-pyrimidinon-derivate
GB9722520D0 (en) * 1997-10-24 1997-12-24 Pfizer Ltd Compounds
DE10238723A1 (de) 2002-08-23 2004-03-11 Bayer Ag Phenyl-substituierte Pyrazolyprimidine
DE10238724A1 (de) 2002-08-23 2004-03-04 Bayer Ag Alkyl-substituierte Pyrazolpyrimidine
DE10238722A1 (de) 2002-08-23 2004-03-11 Bayer Ag Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse
AU2004235915B2 (en) 2003-05-09 2010-08-05 Boehringer Ingelheim International Gmbh 6-cyclylmethyl- and 6-alkylmethyl-substituted pyrazolopyrimidines
US7872124B2 (en) 2004-12-21 2011-01-18 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
WO2007025103A2 (en) 2005-08-23 2007-03-01 Intra-Cellular Therapies, Inc. Organic compounds for treating reduced dopamine receptor signalling activity
JP5837278B2 (ja) 2006-12-05 2015-12-24 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 新規使用
PT2152712E (pt) 2007-05-11 2012-02-29 Pfizer Compostos amino-heterocíclicos
US20090143391A1 (en) 2007-11-30 2009-06-04 Norbert Hofgen Aryl and heteroaryl fused imidazo [1,5-a] pyrazines as inhibitors of phosphodiesterase 10
MX2011005934A (es) 2008-12-06 2011-12-16 Intra Cellular Therapies Inc Compuestos organicos.
US9434730B2 (en) 2010-05-31 2016-09-06 Intra-Cellular Therapies, Inc. PDE1 inhibitor compounds
EP3181566A1 (en) 2010-09-20 2017-06-21 Ironwood Pharmaceuticals, Inc. Imidazotriazinone compounds
EP2619204A4 (en) 2010-09-21 2014-08-27 Merck Sharp & Dohme TRIAZOLOPYRAZINONE AS P2X7 RECEPTOR ANTAGONISTS
JO3089B1 (ar) 2010-11-19 2017-03-15 H Lundbeck As مشتقات ايميدازول كمثبطات لانزيمات pde10a
JP6051210B2 (ja) 2011-06-10 2016-12-27 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
HK1211023A1 (zh) * 2011-10-10 2016-05-13 H. Lundbeck A/S 具有咪唑并吡嗪骨架pde9i
HK1199879A1 (en) 2012-01-26 2015-07-24 H.隆德贝克有限公司 Pde9 inhibitors with imidazo triazinone backbone
US9499562B2 (en) 2012-06-18 2016-11-22 Dart Neuroscience (Cayman) Ltd. Substituted thiophene- and furan-fused azolopyrimidine-5-(6H)-one compounds
ES2836129T3 (es) 2013-03-15 2021-06-24 Intra Cellular Therapies Inc Compuestos orgánicos
JP5783297B2 (ja) 2013-08-06 2015-09-24 株式会社デンソー 力学量センサ
JP5797815B1 (ja) 2014-06-27 2015-10-21 細田建設株式会社 後施工アンカー及びその施工方法
US20170273985A1 (en) 2014-09-18 2017-09-28 Sunovion Pharmaceuticals Inc. Tricyclic derivative
US20160083400A1 (en) 2014-09-18 2016-03-24 Sunovion Pharmaceuticals Inc. Tricyclic guanidine derivative
US20160083391A1 (en) 2014-09-18 2016-03-24 Sunovion Pharmaceuticals Inc. Tricyclic piperazine derivative
TW201629064A (zh) 2014-10-10 2016-08-16 Ｈ 朗德貝克公司 作爲ｐｄｅ１抑制劑之三唑並吡酮
US20180044343A1 (en) 2015-03-16 2018-02-15 Sumitomo Dainippon Pharma Co., Ltd. Bicyclic imidazolo derivative
TW201643167A (zh) 2015-04-22 2016-12-16 Ｈ 朗德貝克公司 作爲ｐｄｅ１抑制劑之咪唑並三酮
JO3627B1 (ar) 2015-04-30 2020-08-27 H Lundbeck As إيميدازو بيرازينونات على هيئة مثبطات pde1
TWI609870B (zh) 2016-02-12 2018-01-01 美國禮來大藥廠 Pde1抑制劑
TWI729109B (zh) 2016-04-12 2021-06-01 丹麥商Ｈ 朗德貝克公司 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮
JP2018076285A (ja) 2016-09-14 2018-05-17 大日本住友製薬株式会社 二環性イミダゾロ誘導体を含む医薬
EP3529250B1 (en) 2016-10-18 2023-12-06 H. Lundbeck A/S Imidazopyrazinones, pyrazolopyrimidinones and pyrazolopyridinones as pde1 inhibitors
WO2018078042A1 (en) 2016-10-28 2018-05-03 H. Lundbeck A/S Combination treatments comprising administration of imidazopyrazinones
HUE050403T2 (hu) 2016-10-28 2020-12-28 H Lundbeck As Imidazopirazinonokkal végzett kombinációs kezelések pszichiátriai és/vagy kognitív betegségek kezelésére

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101983199A (zh) * 2008-04-02 2011-03-02 贝林格尔.英格海姆国际有限公司 1-杂环基-1，5-二氢-吡唑并[3，4-d]嘧啶-4-酮衍生物及其作为pde9a调节剂的用途
CN102143965A (zh) * 2008-09-08 2011-08-03 贝林格尔.英格海姆国际有限公司 吡唑并嘧啶酮及其在治疗中枢神经系统疾病中的用途
CN102292340A (zh) * 2009-01-26 2011-12-21 辉瑞大药厂 用作pde9 抑制剂的氨基-杂环类化合物

Also Published As

Publication number Publication date
ES2967489T3 (es) 2024-04-30
EP3529250A1 (en) 2019-08-28
JP2019534324A (ja) 2019-11-28
CN109843884A (zh) 2019-06-04
US10633382B2 (en) 2020-04-28
EP3529250B1 (en) 2023-12-06
WO2018073251A1 (en) 2018-04-26
US20190308968A1 (en) 2019-10-10
JP7112413B2 (ja) 2022-08-03

Similar Documents

Publication Publication Date Title
CN109843884B (zh) 作为pde1抑制剂的咪唑并吡嗪酮、吡唑并嘧啶酮和吡唑并吡啶酮
CN104395315B (zh) 作为LRRK2抑制剂的4-(取代的氨基)-7H-吡咯并〔2,3-d〕嘧啶类
CN109071549B (zh) Pde1抑制剂
JP2023538060A (ja) 二環化合物、それを含む組成物、及びそれらの使用
EP3558988B1 (en) Pyrazolo[3,4-b]pyridines and imidazo[1,5-b]pyridazines as pde1 inhibitors
CN111491936B (zh) 作为pde1抑制剂的大环化合物
TW201806950A (zh) 作爲ＰＤＥ１抑制劑之１Ｈ－吡唑并［４，３－ｂ］吡啶
JP7698676B2 (ja) デルタ－５デサチュラーゼ阻害剤としての複素環式化合物及び使用方法
CN111511742B (zh) 作为PDE1抑制剂的吡唑并[4,3-b]吡啶和咪唑并[1,5-a]嘧啶
CN110818683A (zh) 2-吡啶取代脲结构小分子化合物及其合成和应用
HK40011732B (en) Pyrazolo[3,4-b]pyridines and imidazo[1,5-b]pyridazines as pde1 inhibitors
HK40011732A (en) Pyrazolo[3,4-b]pyridines and imidazo[1,5-b]pyridazines as pde1 inhibitors
HK1213885B (en) Imidazo-triazine derivatives as pde10 inhibitors
HK1213885A1 (zh) 作爲pde10抑制剂的咪唑并-三嗪衍生物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20220304

CF01 Termination of patent right due to non-payment of annual fee